About

Gemma Budd is the General Manager of Nanopharm, an Aptar Pharma company, responsible for formulation development and analytical services of orally inhaled and nasal drug products. With a degree in biomedical sciences, Ms Budd has over 12 years of experience in the pharmaceutical industry in both research and commercial positions, from materials science and analytical services to formulation technology and drug delivery devices, primarily for oral and inhaled dosage forms.

Contributions

RESPIRATORY

ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS

Gemma Budd and Julie Suman, consider the key issues that preclinical and clinical trials for orally inhaled and nasal drug products must address within the context of the information that regulators are looking for, providing insight, strategies and advice for both novel and generic products in this sector.

More contributions

NASAL

STEPS TO SUCCESS IN NOSE-TO-BRAIN DRUG DELIVERY

Reenal Gandhi and Gemma Budd consider the multiple hurdles associated with developing nasal drug delivery solutions, current understanding of the associated biology and the advantages of alternative device designs and state-of-the-art formulation practice.